SIGNATURES for Synta_Pharmaceuticals (SNTA)

Send us Feedback

Synta Pharmaceuticals (SNTA)

	SUMMARY

	BULLS

	BEARS

	TOPICS

	DATA CENTRAL

	STOCK CHART

	SEC FILINGS

	BALANCE

	INCOME

	CASH FLOW

SNTA » Topics » SIGNATURES

This excerpt taken from the SNTA 8-K filed Oct 27, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: October 27, 2009	/s/ Keith S. Ehrlich
	Keith S. Ehrlich
	Vice President, Finance and Administration
	Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Jul 13, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: July 13, 2009	/s/ Safi R. Bahcall
	Safi R. Bahcall
	President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Jun 19, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: June 19, 2009	/s/ Keith S. Ehrlich
	Keith S. Ehrlich
	Vice President, Finance and Administration Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Jun 15, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: June 15, 2009	/s/ Keith S. Ehrlich
	Keith S. Ehrlich
	Vice President, Finance and Administration
	Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Apr 17, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: April 17, 2009	/s/ Safi R. Bahcall
	Safi R. Bahcall
	President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Mar 26, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: March 26, 2009	/s/ Safi R. Bahcall
	Safi R. Bahcall
	President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Mar 19, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: March 19, 2009	/s/ Keith S. Ehrlich
	Keith S. Ehrlich
	Vice President, Finance and Administration, Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Mar 18, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SYNTA PHARMACEUTICALS CORP.


Dated: March 18, 2009		/s/ Safi R. Bahcall
		Safi R. Bahcall, Ph.D.
		President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Feb 27, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: February 27, 2009	/s/ Safi R. Bahcall
	Safi R. Bahcall, Ph.D.
	President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Dec 30, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SYNTA PHARMACEUTICALS CORP.


Dated: December 30, 2008		/s/ Safi R. Bahcall
		Safi R. Bahcall, Ph.D.
		President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Apr 29, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: April 29, 2008	/s/ Safi R. Bahcall
	Safi R. Bahcall, Ph.D.
	President and Chief Executive Officer

This excerpt taken from the SNTA 8-K filed Apr 18, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SYNTA PHARMACEUTICALS CORP.


Dated: April 18, 2008		/s/ Keith S. Ehrlich
		Keith S. Ehrlich
		Vice President, Finance and Administration
		Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Oct 12, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.


Dated: October 11, 2007	/s/ Safi R. Bahcall
	Safi R. Bahcall, Ph.D.
	President and Chief Executive Officer

This excerpt taken from the SNTA 10-Q filed Aug 6, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SYNTA PHARMACEUTICALS CORP.
Date: August 6, 2007	By:	/s/ SAFI R. BAHCALL
		Safi R. Bahcall, Ph.D.
		President and Chief Executive Officer
		(principal executive officer)
Date: August 6, 2007	By:	/s/ KEITH S. EHRLICH
		Keith S. Ehrlich, C.P.A.
		Vice President Finance and Administration,
		Chief Financial Officer (principal
		accounting and financial officer)

This excerpt taken from the SNTA 8-K filed Jul 23, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SYNTA PHARMACEUTICALS CORP.

Dated: July 23, 2007		/s/ Keith S. Ehrlich
		Keith S. Ehrlich
		Vice President, Finance and Administration Chief Financial Officer

This excerpt taken from the SNTA 8-K filed Mar 2, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		SYNTA PHARMACEUTICALS CORP.

Dated: March 2, 2007		/s/ Safi R. Bahcall
		Safi R. Bahcall
		President and Chief Executive Officer

Synta Pharmaceuticals (SNTA)

SNTA » Topics » SIGNATURES

EXCERPTS ON THIS PAGE:

RELATED TOPICS for SNTA: